参芪扶正注射液治疗老年慢性心力衰竭的临床疗效及安全性

参芪扶正注射液治疗老年慢性心力衰竭的临床疗效及安全性陈福军;陈力超
【期刊名称】《中国生化药物杂志》
【年(卷),期】2017(000)004
【摘要】目的探讨参芪扶正注射液治疗老年慢性心力衰竭的临床疗效及安全性.方法选取2014年9月～2015年9月平阳县中医院收治的58 例老年慢性心力衰竭患者,随机分为对照组及试验组,各29 例;对照组给予常规治疗,试验组在对照组基础上加用参芪扶正注射液250 mL,每天1 次,静脉滴注;比较2 组患者治疗前后血清肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)水平、治疗有效率及安全性.结果治疗后,与对照组比较,试验组患者血清TNF-α及IL-1β水平较低(P<.0.05).试验组的治疗有效率为93.11％显著高于对照组的65.52％ (P<.0.05).结论参芪扶正注射液能够显著降低老年慢性心力衰竭患者的血清TNF-α及IL-1β水平,减轻炎症反应,提高临床疗效,且安全性较高.%Objective To evaluate the clinical curative effect and safety of Shenqifuzheng injection in the treatment of elderly patients with chronic heart failure.Methods 58 cases of elderly patients with chronic heart failure were selected from September 2014 to September 2015 in our hospital and randomly divided into the control group and treatment group,29 cases in each group.The control group was given conventional therapy,on the basis of the control group,the experimental group was treated with Shenqifuzheng injection,250mL,one time a day,intravenous drip;Before and after treatment,compared between the two groups of patients with serum tumor necrosis factorα(TNF-α),interleukin 1β
levels,efficiency of treatment and safety.Results After treatment,compared with the control group,the serum levels of TNF-α and IL-1β we re lower in the experimental group(P<0.05); the treatment efficiency of the experimental group(93.11％)was significantly higher than that of the control group(65.52％,P<0.05).Conclusion The Shenqifuzheng injection can significantly reduce the serum levels of TNF-α and IL-1βin elderly patients with chronic heart failure,reduce inflammatory reaction,improve clinical efficacy,and safety was high.
【总页数】3页(P137-139)
【作者】陈福军;陈力超
【作者单位】平阳县中医院中药房,浙江温州 325401;平阳县中医院内科,浙江温州 325401
【正文语种】中文
【中图分类】R259
【相关文献】
1.参芪扶正注射液治疗腹腔镜胃癌术后患者的临床疗效及安全性 [J], 卓恩挺;王连臣;陈雪莲;符国宏;刘松平
2.左西孟旦治疗老年慢性心力衰竭的临床疗效及安全性 [J], 李同社;高振华;杨智宏;靳飞鹏
3.贝那普利与螺内酯联合用药方案治疗老年慢性心力衰竭的临床疗效及安全性评价[J], 刘淑娟;
4.贝那普利与螺内酯联合用药方案治疗老年慢性心力衰竭的临床疗效及安全性评价[J], 刘淑娟
5.心脉隆注射液治疗老年慢性心力衰竭的临床疗效及安全性分析 [J], 仝峰;司大妞;乔雯雯;陈建涛
因版权原因，仅展示原文概要，查看原文内容请购买。